Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raju Mohan

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|December 4, 2014
Pharmacological characterization of a novel liver X receptor agonist with partial LXRα activity and a favorable window in nonhuman primatesTodd G Kirchgessner, Richard Martin, Paul Sleph, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2018
Reversible, orally available ADP receptor (P2Y<sub>12</sub>) antagonists Part I: Hit to lead processImadul Islam, Shendong Yuan, Robert G Wei, et al.
Journal of Medicinal Chemistry|January 23, 2009
Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR)Brenton Flatt, Richard Martin, Tie-Lin Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 9, 2004
Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligandPatricia J Willy, Ian R Murray, Jing Qian, et al.
Bioorganic & Medicinal Chemistry Letters|December 2, 2014
Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβEllen Kick, Richard Martin, Yinong Xie, et al.
Journal of Medicinal Chemistry|May 31, 2002
Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groupsGary Phillips, William J Guilford, Brad O Buckman, et al.
Bioorganic & Medicinal Chemistry Letters|October 7, 2011
Discovery of a new class of glucosylceramide synthase inhibitorsElena Koltun, Steven Richards, Vicky Chan, et al.
Bioorganic & Medicinal Chemistry|January 30, 2002
Design, synthesis, and biological activity of novel factor Xa inhibitors: 4-aryloxy substituents of 2,6-diphenoxypyridinesHoward P Ng, Brad O Buckman, Keith A Eagen, et al.
Journal of Medicinal Chemistry|April 14, 2012
Discovery and characterization of an inhibitor of glucosylceramide synthaseSteven Richards, Christopher J Larson, Elena S Koltun, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Discovery of Highly Potent Liver X Receptor β AgonistsEllen K Kick, Brett B Busch, Richard Martin, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Pharmacology and Experimental Therapeutics|December 4, 2014
Pharmacological characterization of a novel liver X receptor agonist with partial LXRα activity and a favorable window in nonhuman primatesTodd G Kirchgessner, Richard Martin, Paul Sleph, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2018
Reversible, orally available ADP receptor (P2Y<sub>12</sub>) antagonists Part I: Hit to lead processImadul Islam, Shendong Yuan, Robert G Wei, et al.
Journal of Medicinal Chemistry|January 23, 2009
Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR)Brenton Flatt, Richard Martin, Tie-Lin Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 9, 2004
Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligandPatricia J Willy, Ian R Murray, Jing Qian, et al.
Bioorganic & Medicinal Chemistry Letters|December 2, 2014
Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβEllen Kick, Richard Martin, Yinong Xie, et al.
Journal of Medicinal Chemistry|May 31, 2002
Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groupsGary Phillips, William J Guilford, Brad O Buckman, et al.
Bioorganic & Medicinal Chemistry Letters|October 7, 2011
Discovery of a new class of glucosylceramide synthase inhibitorsElena Koltun, Steven Richards, Vicky Chan, et al.
Bioorganic & Medicinal Chemistry|January 30, 2002
Design, synthesis, and biological activity of novel factor Xa inhibitors: 4-aryloxy substituents of 2,6-diphenoxypyridinesHoward P Ng, Brad O Buckman, Keith A Eagen, et al.
Journal of Medicinal Chemistry|April 14, 2012
Discovery and characterization of an inhibitor of glucosylceramide synthaseSteven Richards, Christopher J Larson, Elena S Koltun, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Discovery of Highly Potent Liver X Receptor β AgonistsEllen K Kick, Brett B Busch, Richard Martin, et al.
Pageof 3